Table 1.

Drug resistance mutations detected at baseline by population sequencing

Subject	GT	Dose (mg)a	Sequencing method	Baseline RAM(s)b	Max VL reduction (log10 HCV RNA IU/ml) in:c
					Subject	Cohort
AS	1b	10	Population	L31M	2.09	3.31
X	1a	30	Population	K24K/R	2.64	3.01
AC	1a	30	Population	Q30E/Q	0.88	3.01
BM	1a	90	Population	L31M	0.16	3.01
Q	1a	10	454	Y93C (12%)	1.60	3.09
AU	1b	10	454	Y93H (1.3%)	2.28	3.31
AZ	1a	PBO	Population	L31L/M	0.25	0.03
BH	1b	PBO	Population	L31M	0.15	0.03

^aPBO, placebo.

^bResistance-associated mutations (RAMs) are defined as any substitution occurring at NS5A amino acid positions 24, 25, 28, 30, 31, 58, 62, and 93.

^cMax, maximum; VL, viral load.